ArticleBreast cancer research and treatment1995
The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases.
Article in Breast cancer research and treatment, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 182 citations in OpenAlex.
- Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Trial
- ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer.Breast cancer research : BCR · 2012Trial
- Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy.Breast cancer research : BCR · 2006Trial
- c-erb-B2 expression and response to treatment in metastatic breast cancer.Medical oncology (Northwood, London, England) · 2000Trial
- Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.British journal of cancer · 1996Trial
- Cell lineage tracing links ERα loss in Erbb2-positive breast cancers to the arising of a highly aggressive breast cancer subtype.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Considerations for feature selection using gene pairs and applications in large-scale dataset integration, novel oncogene discovery, and interpretable cancer screening.BMC medical genomics · 2020Article
- A nomogram to predict HER2 status in breast cancer patients with HER2-borderline disease as determined via immunohistochemistry.Oncotarget · 2017Article
- Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant mammary tissues of MMTV-erbB-2 transgenic mice.Journal of experimental & clinical cancer research : CR · 2017Article
- Evaluation of prognostic factors and survival rates in malignant feline mammary gland neoplasms.Journal of feline medicine and surgery · 2016Article
- Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes.Journal of Cancer · 2016Review
- Inverse regulation of EGFR/HER1 and HER2-4 in normal and malignant human breast tissue.PloS one · 2013Article
- Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debate.Medical oncology (Northwood, London, England) · 2011Review
- Testing for HER2 in Breast Cancer: A Continuing Evolution.Pathology research international · 2010Article
- Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers.Virchows Archiv : an international journal of pathology · 2010Article
- The prognostic role of phospho-Src family kinase analysis in tongue cancer.Journal of cancer research and clinical oncology · 2010Article
- The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancers.Current oncology (Toronto, Ont.) · 2009Article
- The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.Experimental and molecular pathology · 2009Review
- The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer.Current oncology (Toronto, Ont.) · 2009Article
- Reduction in HER-2 protein expression in a breast tumor HER-2 positive after only one injection of Trastuzumab: a case report.Cases journal · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To assess the practical prognostic value of c-erbB2, we performed a study on 942 invasive ductal carcinomas treated with primary surgery between 1980 and 1986 in our center. We evaluated its expression by immunohistochemistry in paraffin-embedded tissue using a polyclonal antipeptide antibody. Of 942 tumors, 229 (24%) showed a positive membrane staining. We observed a significant association between c-erbB2 and Scarff-Bloom-Richardson grading (p < 0.0001) and a negative correlation between c-erbB2 and both estrogen and progesterone receptors (p < 0.0001). In our analysis, with respect to overall survival (OS), relapse-free survival (RFS), and metastasis-free survival (MFS), c-erbB2 was statistically significant (p < or = 0.0001) for the whole group and the node-positive subgroup. In multivariate analysis, c-erbB2 appeared to be an independent variable for RFS and MFS in the node-negative group. However, in our hands, c-erbB2 had a poor prognostic value in comparison with the classical prognostic variables such as histological grade, nodal status (N), hormonal receptor status (estrogen and progesterone receptors), and tumor size, and it did not supersede the classical parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.